Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel – AJMC.com Managed Markets Network
|
Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel
AJMC.com Managed Markets Network Novartis' chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced … |
